|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2008-9-30
|
|
pubmed:abstractText |
The current therapy concept for metastatic bladder cancer is chemotherapy with gemcitabine and cisplatin as the first line protocol. Within the last 20 years no real progress could be achieved; the median survival is 14 months, though many different protocols have been tested. Expression analyses of growth factor receptors in human tumor tissue showed that expression of certain receptors is correlated with a severe clinical course.For many of these growth factor receptors pharmacological inhibitors are available in order to perform targeted therapy. The following review gives a survey of current studies on targeted therapy of metastatic bladder carcinoma.
|
|
pubmed:language |
ger
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Benzenesulfonates,
http://linkedlifedata.com/resource/pubmed/chemical/Pyridines,
http://linkedlifedata.com/resource/pubmed/chemical/Quinazolines,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Growth Factor,
http://linkedlifedata.com/resource/pubmed/chemical/bevacizumab,
http://linkedlifedata.com/resource/pubmed/chemical/gefitinib,
http://linkedlifedata.com/resource/pubmed/chemical/lapatinib,
http://linkedlifedata.com/resource/pubmed/chemical/sorafenib,
http://linkedlifedata.com/resource/pubmed/chemical/trastuzumab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0340-2592
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
47
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1311-4
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:18587555-Antibodies, Monoclonal,
pubmed-meshheading:18587555-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:18587555-Antineoplastic Agents,
pubmed-meshheading:18587555-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18587555-Benzenesulfonates,
pubmed-meshheading:18587555-Carcinoma, Transitional Cell,
pubmed-meshheading:18587555-Disease Progression,
pubmed-meshheading:18587555-Drug Delivery Systems,
pubmed-meshheading:18587555-Humans,
pubmed-meshheading:18587555-Pyridines,
pubmed-meshheading:18587555-Quinazolines,
pubmed-meshheading:18587555-Receptor, erbB-2,
pubmed-meshheading:18587555-Receptors, Growth Factor,
pubmed-meshheading:18587555-Survival Rate,
pubmed-meshheading:18587555-Urinary Bladder Neoplasms
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
[Targeted therapy for metastatic bladder cancer].
|
|
pubmed:affiliation |
Klinik und Poliklinik für Urologie, Universitätsklinikum, Hufelandstrasse 55, 45122 Essen, Deutschland. frankvomDorp@web.de
|
|
pubmed:publicationType |
Journal Article,
English Abstract
|
